DISCO Pharmaceuticals
The surfaceome company
DISCO employs a disruptive proteomics technology to map the surfaceome of cancer cells and develop first-in-class cancer drugs. With the advent of new cell-surface, target-directed therapeutic modalities, it is critical to ramp up the discovery of meaningful targets. DISCO does so by comprehensively identifying druggable targets and protein communities (i.e., different proteins that form nanoscale organizations on a cell), across the entire cancer cell surface at scale, thus uncovering crucial new information that neither genome nor transcriptome sequencing can provide. By knowing which proteins are truly present on the cell surface, and how they are associated within protein communities, DISCO can design highly specific binders, boosting expected efficacy and reducing side effects.
DISCO is backed by world leading life sciences investors including M Ventures, Sofinnova Partners, Panakes Partners and AbbVie Ventures.
